Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec;43(12):1428-1437.
doi: 10.1111/pace.14097. Epub 2020 Nov 29.

Leadless pacemaker: State of the art and incoming developments to broaden indications

Antonio Curnis  1 , Francesca Salghetti  1 , Manuel Cerini  1 , Davide Fabbricatore  1 , Giulia Ghizzoni  1 , Luca Arrigoni  1 , Greta Generati  1 , Gianmarco Arabia  1 , Vincenzo Maiolo  1 , Mohamed Aboelhassan  2 , Luca Bontempi  1
Affiliations
Review

Leadless pacemaker: State of the art and incoming developments to broaden indications

Antonio Curnis et al. Pacing Clin Electrophysiol. 2020 Dec.

Abstract

Theleadless pacemaker (LLPM) therapy has been developed in recent years to overcome the transvenous lead and device pocket-related complications. The LLPMs now available are self-contained right ventricular pacemakers and are limited to single-chamber ventricular pacing modality. This literature review deals with the current status of LLPM technology and current areas of clinical applicability. The safety and efficacy outcomes published from randomized clinical trials and real world registries are analyzed and compared with historical conventional transvenous pacemaker data. Furthermore, new pacing modalities and future perspectives to broaden the clinical use and cover most of pacing indications are discussed. Due to the overall safe and effective profile in the short term and intermediate term, also in fragile patients, the LLPM use is constantly growing in daily clinical practice. Actually, it can be considered a landmark innovation, through which a new era of cardiac pacing has begun.

Keywords: Micra TPS; Nanostim LCP; bradyarrhythmias; leadless pacemaker.

PubMed Disclaimer

References

REFERENCES

    1. Brignole M, Auricchio A, Baron-Esquivias G, et al. ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Europace. 2013;15(8):1070-1118.
    1. Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2019 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay. A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74(7):932-987.
    1. Kiviniemi MS, Pirnes MA, Eränen HJ, Kettunen RV, Hartikainen JE. Complications related to permanent pacemaker therapy. Pacing Clin Electrophysiol. 1999;22:711-720.
    1. Ellenbogen KA, Hellkamp AS, Wilkoff BL, et al. Complications arising after implantation of DDD pacemakers: the MOST experience. Am J Cardiol. 2003;92:740-741.
    1. Udo EO, Zuithoff NP, van Hemel NM, et al. Incidence and predictors of short- and long-term complications in pacemaker therapy: the FOLLOWPACE study. Heart Rhythm. 2012;9(5):728-735.

LinkOut - more resources